Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus

Keiko Ono; Hitoshi Suzushima; Yuko Watanabe; Yoshitaka Kikukawa; Taizou Shimomura; Noboru Furukawa; Tatsuya Kawaguchi; Eiichi Araki

doi:10.2169/internalmedicine.51.8314

CASE REPORTS

Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus

Keiko Ono, Hitoshi Suzushima, Yuko Watanabe, Yoshitaka Kikukawa, Taizou Shimomura, Noboru Furukawa, Tatsuya Kawaguchi, Eiichi Araki

Author information

Keiko Ono
Department of Metabolism and Endocrinology, Kumamoto Shinto General Hospital (formerly NTT West Kyushu Hospital), Japan
Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Japan
Hitoshi Suzushima
Department of Hematology, Kumamoto Shinto General Hospital (formerly NTT West Kyushu Hospital), Japan
Yuko Watanabe
Department of Hematology, Kumamoto Shinto General Hospital (formerly NTT West Kyushu Hospital), Japan
Yoshitaka Kikukawa
Department of Hematology, Kumamoto Shinto General Hospital (formerly NTT West Kyushu Hospital), Japan
Taizou Shimomura
Department of Hematology, Kumamoto Shinto General Hospital (formerly NTT West Kyushu Hospital), Japan
Noboru Furukawa
Center for Medical Education and Research, Faculty of Life Sciences, Kumamoto University, Japan
Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Japan
Tatsuya Kawaguchi
Department of Hematology and Infectious Diseases, Kumamoto University Hospital, Japan
Eiichi Araki
Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Japan

Keywords: type 2 diabetes mellitus, tyrosine kinase inhibitors, chronic myeloid leukemia, insulin secretion, insulin sensitivity

JOURNAL OPEN ACCESS

2012 Volume 51 Issue 19 Pages 2763-2766

DOI https://doi.org/10.2169/internalmedicine.51.8314

Details

Abstract

Tyrosine kinase inhibitors (TKIs) have been shown to affect glucose metabolism in patients with chronic myeloid leukemia (CML); however, their precise mechanism of action remains unknown. We herein report the case of a 57-year-old diabetic CML patient who was resistant to imatinib and initially required 20 units of insulin daily to control his blood glucose levels. After the initiation of dasatinib, the patient's insulin requirements declined rapidly and insulin treatment was discontinued within two weeks. Meanwhile, the fasting C-peptide immunoreactivity increased two-fold, suggesting that dasatinib facilitated the recovery of insulin production. Dasatinib may therefore be beneficial for diabetic CML patients, especially those who require insulin treatment.

Corresponding author

Register with J-STAGE for free!